Skip to content
Agentic OS
Menu

Intelligence / Healthtech / PMA Approvals / Medibeacon, INC.

Approvalsdevice change approved (PMA)2 Oct 2026

Medibeacon, INC.

2 Oct 2026: Device change approved (PMA) · MediBeacon Transdermal GFR System. Recorded in the openFDA device PMA data.

View the source record

Decided
2 Oct 2026
Device
MediBeacon Transdermal GFR System
Specialty
Gastroenterology, Urology
Type
Supplement (Special (Immediate Track))
Reason
Process Change - Manufacturer/Sterilizer/Packager/Supplier
Reference
P230019 S005
Location
St. Louis, MO
What this signal means

A PMA approval is a high-risk device launch: reimbursement, distribution, clinical training and sales hires follow.

  1. Cardiovascular leads with 53 of 120, then Pathology (15).
  2. 35 added in the 30 days to 18 Nov 2026.
Reach them with AOS

Find the decision makers at Medibeacon, INC.

AOS maps the buying committee, finds verified work emails and drafts outreach that cites this approvals signal, for your approval.

Start free

More in Gastroenterology, Urology

PMA Approvals

See all

Source: openFDA device PMA data, data to 18 Nov 2026. Class III devices approved by FDA: original approvals and supplements that change the device (180-day, panel-track and special tracks). 30-day manufacturing notices are left out. AOS shows what the public record says; it does not verify or endorse the company.